Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 18/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 17/20 | 0.46 |
| ▸ | PDE4A | P27815 | 15/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 15/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1430303 | 0.89 | PDE4B (0.48) | PDE4BPDE4DPDE4APDE4CMAPK13 | |
| SCHEMBL1429299 | 0.87 | PDE4B (0.44) | PDE4BPDE4DPDE4APDE4CMAPK13 | |
| SCHEMBL1430117 | 0.85 | KCNK3 (0.52) | — | |
| SCHEMBL1430601 | 0.85 | PDE4B (0.46) | PDE4BPDE4DPDE4APDE4CMAPK13 | |
| SCHEMBL15346997 | 0.84 | SLC2A2 (0.40) | — | |
| SCHEMBL2225808 | 0.82 | SLC2A1 (0.49) | PDE4D | |
| SCHEMBL2179254 | 0.79 | CYP1A2 (0.52) | — | |
| SCHEMBL1430262 | 0.75 | PDE4B (0.48) | PDE4BPDE4DPDE4APDE4CMAPK13 | |
| SCHEMBL1430606 | 0.73 | PDE4B (0.44) | PDE4BPDE4DPDE4APDE4CMAPK13 | |
| SCHEMBL1427429 | 0.73 | KDM4E (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. | 2013-10-31 | — | — | US | disclosed |
| US-8497278-B2 | Imidazo[1,2-a]pyridine compounds | SUNOVION PHARMACEUTICALS INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-07-07 | — | — | US | disclosed |
| EP-2300470-A2 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS GABA-A RECEPTOR MODULATORS | Sepracor Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009143156-A2 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SEPRACOR INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | PDE4B 230/4885PDE4D 454/4885PDE4A 216/4885 |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | PDE4B 230/4885PDE4D 454/4885PDE4A 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.